Article

Lecia V. Sequist Provides an Overview of T790M Mutations in NSCLC

Author(s):

Lecia V. Sequist

Lecia V. Sequist, associate professor of medicine, Massachusetts General Hospital, provides an overview of T790M, a mutation in the epidermal growth factor receptor (EGFR) gene.

Lecia V. Sequist, associate professor of medicine, Massachusetts General Hospital, provides an overview of T790M, a mutation in the epidermal growth factor receptor (EGFR) gene. T790M is the primary cause of treatment resistance in EGFR-positive patients with non-small cell lung cancer (NSCLC).

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of man with text.
An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.
After ovarian cancer surgery, Mary Barbera spent three months in rehab before finally returning home, a milestone that marked her emotional recovery.
Terry Gillespie said the hardest parts of her cancer journey were the isolation, the impact of chemotherapy, and how unprepared she felt despite good guidance.
Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.
Outpatient CAR T-cell therapy has reduced hospital stays by two-thirds while maintaining safety for those with blood cancers, according to Dr. Olalekan Oluwole.
Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Image of women with text.
The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.
Related Content
Quality-of-life in lung cancer varies based on treatment and disease stage: © stock.adobe.com.
July 18th 2025

Lung Cancer Study Links Treatment History to Quality-of-Life Differences

Spencer Feldman
Quality-of-life in lung cancer varies, with certain treatments leading to sleep-related issues, pain, and emotional changes depending on disease stage.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
Image of woman.
July 11th 2025

Facing Breast and Lung Cancer Led Me to a New Purpose in Life

Sue McCarthy
I was diagnosed with breast cancer, then lung cancer 17 years later — and both ultimately led me to make meaningful, positive changes in my life.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
The FDA approved Zegfrovy for advanced NSCLC with EGFR exon 20 mutations after chemotherapy: stock.adobe.com.
July 2nd 2025

Zegfrovy FDA Approved for EGFR Exon 20 Non-Small Cell Lung Cancer

Spencer Feldman
The FDA approved Zegfrovy for advanced non-small cell lung cancer with EGFR exon 20 mutations after chemotherapy.
Image of lung.
June 30th 2025

June Lung Cancer Highlights: Top 5 Updates Patients Should Know

Ryan Scott
During June, investigators reported new data that has advanced the treatment landscape for lung cancer, including new FDA approvals and priority reviews.